nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.10.2004 | Original Article

A 4-methyl-substituted meta-iodobenzylguanidine analogue with prolonged retention in human neuroblastoma cells

verfasst von: Ganesan Vaidyanathan, Philip C. Welsh, Katia C. Vitorello, Stacey Snyder, Henry S. Friedman, Michael R. Zalutsky

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 10/2004

Einloggen, um Zugang zu erhalten

Abstract

Purpose

As a part of our efforts to develop a meta-iodobenzylguanidine (MIBG) analogue with improved characteristics for the diagnosis and treatment of neuroendocrine tumours, 3-[¹³¹I]iodo-4-methyl-benzylguanidine ([¹³¹I]MeIBG) has been developed. The purpose of this study was to evaluate [¹³¹I]MeIBG in vitro using the uptake-1 positive SK-N-SH neuroblastoma cell line and in vivo in normal mice and mice bearing human neuroblastoma xenografts.

Methods

The ability of SK-N-SH human neuroblastoma cells to retain [¹³¹I]MeIBG in vitro over a period of 4 days, in comparison to [¹²⁵I]MIBG, was determined by a paired-label assay. Paired-label biodistributions of [¹³¹I]MeIBG and [¹²⁵I]MIBG were performed in normal mice as well as in athymic mice bearing SK-N-SH and IMR-32 human neuroblastoma xenografts.

Results

Retention of [¹³¹I]MeIBG by SK-N-SH cells in vitro was increased by factors of 1.2, 1.5, 2.0, 2.5 and 3.1 compared with [¹²⁵I]MIBG at 8, 24, 48, 72 and 96 h, respectively. In normal mice, the uptake of [¹³¹I]MeIBG in the heart was similar to that of [¹²⁵I]MIBG at 1 and 4 h; in contrast, myocardial uptake of [¹³¹I]MeIBG was 1.6-fold higher than that of [¹²⁵I]MIBG (p<0.05) at 24 h. When mice were pre-treated with the uptake-1 inhibitor desipramine (DMI), the heart uptake of both tracers was reduced to about half that in untreated controls at 1 h post injection (p<0.05). The hepatic uptake of [¹³¹I]MeIBG was two- to threefold lower than that of [¹²⁵I]MIBG. On the other hand, blood levels of [¹³¹I]MeIBG were substantially higher (up to sixfold), especially at early time points. Uptake of [¹³¹I]MeIBG in heart and tumour at 1 h in the murine SK-N-SH model was specific and comparable to that of [¹²⁵I]MIBG. However, [¹³¹I]MeIBG uptake was 1.6- to 1.7-fold lower than that of [¹²⁵I]MIBG over 4–48 h. While the uptake of both tracers in IMR32 xenografts was similar, it was not uptake-1 mediated.

Conclusion

Introduction of a methyl group at the 4-position of MIBG seems to be advantageous in terms of higher tumour retention in vitro and lower hepatic uptake in vivo. However, the slower blood clearance of MeIBG may be problematic for some applications.

Patel AD, Iskandrian AE. MIBG imaging. J Nucl Cardiol 2002;9:75–94CrossRefPubMed

Hattori N, Schwaiger M. Metaiodobenzylguanidine scintigraphy of the heart: what have we learnt clinically? Eur J Nucl Med 2000;27:1–6PubMed

Sisson JC, Shulkin BL. Nuclear medicine imaging of pheochromocytoma and neuroblastoma. Q J Nucl Med 1999;43:217–23

Tang HR, Da Silva AJ, Matthay KK, Price DC, Huberty JP, Hawkins RA, Hasegawa BH. Neuroblastoma imaging using a combined CT scanner-scintillation camera and ¹³¹I-MIBG. J Nucl Med 2001;42:237–47

Tepmongkol S, Heyman S. ¹³¹I MIBG therapy in neuroblastoma: mechanisms, rationale, and current status. Med Pediatr Oncol 1999;32:427–31CrossRefPubMed

Mukherjee JJ, Kaltsas GA, Islam N, Plowman PN, Foley R, Hikmat J, Britton KE, Jenkins PJ, Chew SL, Monson JP, Besser GM, Grossman AB. Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with ¹³¹I-meta-iodobenzylguanidine (¹³¹I-mIBG). Clin Endocrinol 2001;55:47–60CrossRef

Matthay KK, DeSantes K, Hasegawa B, Huberty J, Hattner RS, Ablin A, Reynolds CP, Seeger RC, Weinberg VK, Price D. Phase I dose escalation of ¹³¹I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol 1998;16:229–36PubMed

Yanik GA, Levine JE, Matthay KK, Yanik GA, Levine JE, Matthay KK, Sisson JC, Shulkin BL, Shapiro B, Hubers D, Spalding S, Braun T, Ferrara JLM, Hutchinson RJ. Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma. J Clin Oncol 2002;20:2142–9CrossRefPubMed

Vaidyanathan G, Shankar S, Affleck DJ, Welsh PC, Slade SK, Zalutsky MR. Biological evaluation of ring- and side-chain-substituted m-iodobenzylguanidine analogues. Bioconjug Chem 2001;12:798–806CrossRefPubMed

10.

Vaidyanathan G, Affleck DJ, Zalutsky MR. Validation of 4-[fluorine-18]fluoro-3-iodobenzylguanidine as a positron-emitting analog of MIBG. J Nucl Med 1995;36:644–50PubMed

11.

Wieland DM. Radiopharmaceutical design: the adrenal medulla and its diseases. In: Fritzberg AR, ed. Radiopharmaceuticals: progress and clinical perspectives, vol 1. Boca Raton: CRC; 1986:117–53

12.

Sircar I, Duell BL, Bobowski G, Bristol JA, Evans DB. Cardiotonic agents. 2. Synthesis and structure-activity relationships of 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones: a new class of positive inotropic agents. J Med Chem 1985;28:1405–13PubMed

13.

Block MH, Boyer S, Brailsford W, Brittain DR, Carroll D, Chapman S, Clarke DS, Donald CS, Foote KM, Godfrey L, Ladner A, Marsham PR, Masters DJ, Mee CD, O’Donovan MR, Pease JE, Pickup AG, Rayner JW, Roberts A, Schofield P, Suleman A, Turnbull AV. Discovery and optimization of a series of carbazole ureas as NPY5 antagonists for the treatment of obesity. J Med Chem 2002;45:3509–23CrossRefPubMed

14.

Vaidyanathan G, Shankar S, Affleck DJ, Alston K, Norman J, Welsh P, LeGrand H, Zalutsky MR. Meta-iodobenzylguanidine derivatives containing a second guanidine moiety. Bioorg Med Chem 2004;12:1649–56CrossRefPubMed

15.

Jaques S Jr, Tobes MC, Sisson JC, Baker JA, Wieland DM. Comparison of the sodium dependency of uptake of meta-iodobenzylguanidine and norepinephrine into cultured bovine adrenomedullary cells. Mol Pharmacol 1984;26:539–46PubMed

16.

Smets LA, Loesberg C, Janssen M, Metwally EA, Huiskamp R. Active uptake and extravesicular storage of m-iodobenzylguanidine in human neuroblastoma SK-N-SH cells. Cancer Res 1989;49:2941–4PubMed

17.

Wieland DM, Wu J, Brown LE, Mangner TJ, Swanson DP, Beierwaltes WH. Radiolabeled adrenergic neuron-blocking agents: adrenomedullary imaging with [¹³¹I]iodobenzylguanidine. J Nucl Med 1980;21:349–53PubMed

18.

Vaidyanathan G, Zalutsky MR. No-carrier-added synthesis of meta-[¹³¹I]iodobenzylguanidine. Appl Radiat Isot 1993;44:621–8CrossRefPubMed

19.

Biedler JN, Helson L, Spengler BA. Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture. Cancer Res 1973;33:2643–52PubMed

20.

Kaltenbach JP, Kaltenbach MH, Lyons WB. Nigrosin as a dye for differentiating live and dead ascites cells. Exp Cell Res 1958;15:112–7PubMed

21.

Vaidyanathan G, Affleck DJ, Zalutsky MR. Validation of 4-[fluorine-18]fluoro-3-iodobenzylguanidine as a positron-emitting analog of MIBG. J Nucl Med 1995;36:644–50PubMed

22.

Lee H, Inbasekaran MN, Wieland DM, Sherman PS, Fisher SJ, Mangner TJ, Rogers WL, Clinthorne NH. Development of a kit-form analog of metaiodobenzylguanidine. J Nucl Med 1986;27:256–67PubMed

23.

Mairs RJ, Gaze MN, Barrett A. The uptake and retention of metaiodobenzylguanidine by the neuroblastoma cell line NB1-G. Br J Cancer 1991;64:293–5PubMed

24.

Vaidyanathan G, Zhao X-G, Strickland DK, Zalutsky MR. No-carrier-added iodine-131-FIBG: evaluation of an MIBG analog. J Nucl Med 1997;38:330–4PubMed

25.

Kelley SP, Grota LJ, Felten SY, Madden KS, Felten DL. Norepinephrine in mouse spleen shows minor strain differences and no diurnal variation. Pharmacol Biochem Behav 1996;53:141–6CrossRefPubMed

26.

Cano G, Sved AF, Rinaman L, Rabin BS, Card JP. Characterization of the central nervous system innervation of the rat spleen using viral transneuronal tracing. J Comp Neurol 2001;439:1–18CrossRefPubMed

27.

Rutgers M, Tytgat GAM, Verwijs-Janssen M, Buitenhusis C, Voute PA, Smets LA. Uptake of the neuron-blocking agent meta-iodobenzylguanidine and serotonin by human platelets and neuro-adrenergic tumor cells. Int J Cancer 1993;54:290–5PubMed

28.

Glowniak JV, Kilty JE, Amara SG, Hoffman BJ, Turner FE. Evaluation of metaiodobenzylguanidine uptake by the norepinephrine, dopamine and serotonin transporters. J Nucl Med 1993;34:1140–6PubMed

29.

Feldman JM, Frankel N, Coleman RE. Platelet uptake of the pheochromocytoma-scanning agent ¹³¹I-meta-iodobenzylguanidine. Metabolism 1984;33:397–9CrossRefPubMed

30.

Rutgers M, Gubbels AAT, Hoefnagel CA, Voute PA, Smets LA. A human neuroblastoma xenograft model for [¹³¹I]-meta-iodobenzylguanidine (MIBG) biodistribution and targeted radiotherapy. Prog Clin Biol Res 1991;366:471–8PubMed

31.

Khanna C, Jaboin JJ, Drakos E, Tsokos M, Thiele CJ. Biologically relevant orthotopic neuroblastoma xenograft models: primary adrenal tumor growth and spontaneous distant metastasis. In Vivo 2002;16:77–86PubMed

32.

Buck J, Bruchelt G, Girgert R, Treuner J, Niethammer D. Specific uptake of m-[¹²⁵I]iodobenzylguanidine in the human neuroblastoma cell line SK-N-SH. Cancer Res 1995;45:6366–70

33.

Armour A, Mairs RJ, Gaze MN, Wheldon TE. Modification of meta-iodobenzylguanidine uptake in neuroblastoma cells by elevated temperature. Br J Cancer 1994;70:445–8PubMed

34.

Montaldo PG, Raffaghello L, Guarnaccia F, Pistoia V, Garaventa A, Ponzoni M. Increase of metaiodobenzylguanidine uptake and intracellular half-life during differentiation of human neuroblastoma cells. Int J Cancer 1996;67:95–100CrossRefPubMed

35.

Driscoll TA, Flowers JL, Colvin OM. Potentiation of camptothecin-based antineuroblastoma activity by selective tumor acidification [abstract]. Proc Am Assoc Cancer Res 2002; Abstract 2888

36.

Vaidyanathan G, Friedman HS, Keir ST, Zalutsky MR. Localisation of [¹³¹I]MIBG in nude mice bearing SK-N-SH human neuroblastoma xenografts: effects of specific activity. Br J Cancer 1996;73:1171–7PubMed

Titel: A 4-methyl-substituted meta-iodobenzylguanidine analogue with prolonged retention in human neuroblastoma cells
verfasst von: Ganesan Vaidyanathan
Philip C. Welsh
Katia C. Vitorello
Stacey Snyder
Henry S. Friedman
Michael R. Zalutsky
Publikationsdatum: 01.10.2004
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 10/2004
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-004-1596-8

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

A 4-methyl-substituted meta-iodobenzylguanidine analogue with prolonged retention in human neuroblastoma cells

Abstract

Purpose

Methods

Results

Conclusion

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2004

Impact of 131I-SPECT/CT images obtained with an integrated system in the follow-up of patients with thyroid carcinoma

Pre-operative localisation of hyperfunctional parathyroid tissue with 11C-methionine PET

Value of gated SPECT in the analysis of regional wall motion of the interventricular septum after coronary artery bypass grafting

In vitro and in vivo evaluation of the influence of type III NaPi co-transporter activity during apoptosis on 99mTc-(V)DMSA uptake in the human leukaemic cell line U937

Management of thyroid nodules: a clinicopathological, evidence-based approach

Incidence of radiation-induced Graves’ disease in patients treated with radioiodine for thyroid autonomy before and after introduction of a high-sensitivity TSH receptor antibody assay